<DOC>
	<DOCNO>NCT01123876</DOCNO>
	<brief_summary>Assess whether combination ABT-888 FOLFIRI activity subject gastric cancer .</brief_summary>
	<brief_title>Evaluating Safety Tolerability Poly-ADP Ribose ( PARP ) Inhibitor With FOLFIRI Subjects With Solid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>1 . Subject must least 18 year age . 2 . Subjects dose escalation cohort must : * Subjects histologically cytologically confirm malignancy meta static unresectable standard curative measure therapy may provide clinical benefit exist longer effective treatment FOLFIRI viable option . 3 . Subjects expand safety cohort must : * Histological confirm advanced colorectal cancer . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 . 5 . Subject must adequate hematologic , renal hepatic function follow : * Bone Marrow : Absolute neutrophil count ANC &gt; = 1,500/mm3 ; Platelets &gt; = 100,000/mm3 ; Hemoglobin &gt; = 9.5 g/dL ; * Renal function : Serum creatinine &lt; 1.5 * upper normal limit institution 's normal range OR creatinine clearance &lt; = 50 mL/min/1.73m2 subject creatinine level institutional normal ; * Hepatic function : AST ALT &lt; = 2.5 * upper normal limit institution 's normal range . For subject liver metastasis , AST ALT &lt; = 5 * upper normal limit institution 's normal range ; * Bilirubin &lt; = 1.5 * upper normal limit institution 's normal range ; 6 . Partial Thromboplastin Time ( PTT ) must &lt; = 1.5 * upper normal limit institution 's normal range INR &lt; 1.5 . Subjects anticoagulant ( Coumadin ) PTT INR determine investigator . 7 . Women childbearing potential must agree use adequate contraception ( one follow list ) prior study entry , duration study participation 90 day follow completion therapy . Women childbearing potential must negative serum pregnancy test within 21 day prior initiation treatment and/or post menopausal woman must amenorrheic least 12 month consider non childbearing potential . * Total abstinence sexual intercourse ( minimum one complete menstrual cycle ) ; * Vasectomized partner female subject ; * Hormonal contraceptive ( oral , parenteral transdermal ) least 3 month prior study drug administration ; * Doublebarrier method ( condom , contraceptive sponge , diaphragm vaginal ring spermicidal jelly cream ) ; * IUD ( IntraUterine Device ) ; * Additionally , male subject ( include vasectomize ) whose partner pregnant might pregnant must agree use condom duration study 90 day follow completion therapy . 8 . Subject capable understanding comply parameter outline protocol able sign date inform consent , approve Independent Ethics Committee ( IEC ) /Institutional Review Board ( IRB ) , prior initiation screen studyspecific procedure . 9 . The subject receive 3 prior DNA damaging agent cytotoxic chemotherapy treatment ( prior therapy biologic agent include , IL 2 , interferon , vaccine , immunostimulants signal transduction inhibitor allow ) Chemotherapy receive adjuvant therapy 2 year consider prior chemotherapy . 1 . Subject receive anticancer therapy include chemotherapy , immunotherapy , radiotherapy , biologic investigational therapy within 28 day prior study drug administration . Subjects receive hormone therapy , bisphosphonates LHRHagonists eligible . Subjects recover within one grade level ( exceed Grade 2 ) baseline follow significant adverse event toxicity attribute previously anticancer treatment exclude . 2 . Subjects expand safety cohort , previously treat PARP inhibitor . 3 . Subjects know history brain metastasis primary CNS tumor 4 . Subjects know hypersensitivity CPT11 , 5FU Folinic Acid . 5 . Clinically significant uncontrolled major medical condition ( ) include limited : * Uncontrolled nausea/vomiting/diarrhea ; * Active uncontrolled infection ; * Symptomatic congestive heart failure ; * Unstable angina pectoris cardiac arrhythmia ; * Psychiatric illness/social situation would limit compliance study requirement . * Gilbert 's Syndrome * Any medical condition , opinion study investigator , place patient unacceptably high risk toxicity 6 . Subjects treat Ketoconazole , enzymeinducing anticonvulsant , St. John 's Wort . 7 . Subject pregnant lactating . 8 . Subject require parenteral nutrition , tube feed evidence partial bowel obstruction perforation within 28 day prior study drug administration . 9 . The subject another active malignancy within past 3 year except cancer situ Principal Investigator considers cure . 10 . Previous exposure Irinotecan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Gastric Cancer</keyword>
</DOC>